InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,048.42
(
-0.46%
)
US TECH 100
16,978.00
(
0.00%
)
Dow Jones
38,085.80
(
-0.98%
)
Brent Oil
88.34
(
0.21%
)
Bitcoin
64,314.45
(
-0.26%
)
Post# of 251604
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119484
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Monday, 12/22/2014 11:25:58 AM

Monday, December 22, 2014 11:25:58 AM

Post# of 251604
Medivir is still nominally involved in HCV, but the collapse of Simeprevir sales is going to hurt:

http://finance.yahoo.com/news/medivir-miv-802-selected-candidate-074000578.html

Medivir AB (MVIR-B.ST) announced that MIV-802 has been selected as a candidate drug from its hepatitis C virus nucleotide polymerase inhibitor project for the treatment of HCV infection, and is entering non-clinical development.

Simeprevir (which JNJ licensed from Medivir) had a nice run until Harvoni and Viekira Pak were approved, but now it’s merely an asterisk in the HCV marketplace.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up